###begin article-title 0
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin title 2
Objectives:
###end title 2
###begin p 3
###xml 318 326 <span type="species:ncbi:9606">patients</span>
Hepatocyte growth factor (HGF) is a potential key factor in multiple myeloma. Conversion of pro-HGF to its active form is a critical limiting step for its biological effects. We aimed to examine the levels of the most potent activator, the hepatocyte growth factor activator (HGFA), in serum and bone marrow plasma of patients with multiple myeloma.
###end p 3
###begin title 4
Methods:
###end title 4
###begin p 5
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 121 122 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
The activated form of HGFA was measured by an enzyme-linked immunosorbent assay in serum (n= 49) and bone marrow plasma (n= 16) from multiple myeloma patients, and in serum from healthy controls (n= 24).
###end p 5
###begin title 6
Results:
###end title 6
###begin p 7
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The median concentrations of activated HGFA in myeloma and control sera were 39.7 (range 6.2-450.0) and 17.6 ng/mL (range 4.8-280.6), respectively. The difference was statistically significant (P= 0.037). The median concentration of activated HGFA in bone marrow plasma was 6.1 ng/mL (range 3.5-30.0).
###end p 7
###begin title 8
Conclusion:
###end title 8
###begin p 9
###xml 126 134 <span type="species:ncbi:9606">patients</span>
We here show for the first time that the activated form of HGFA is present at high levels in serum and bone marrow of myeloma patients, thus providing a necessary prerequisite for the activation of HGF.
###end p 9
###begin p 10
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
Hepatocyte growth factor (HGF) stimulates survival, proliferation (1), adhesion (2) and migration (3) of malignant plasma cells and is a potential contributor to the bone disease of multiple myeloma (4). HGF is produced by myeloma cells and by stromal cells in the bone marrow microenvironment, and thereby acts in an autocrine or paracrine manner through its receptor c-Met (5-7). We and others have previously shown that serum HGF levels are elevated in myeloma patients compared with normal controls, and associated with poor prognosis (8, 9).
###end p 10
###begin p 11
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
HGF is secreted as a single chain precursor which is proteolytically converted to its biologically active heterodimeric form. The most potent activator is the factor XII-related serine protease hepatocyte growth factor activator (HGFA) (10, 11). HGFA is mainly secreted by the liver, although extrahepatic expression has been reported in a number of normal and tumour tissues (12). It circulates in plasma as a single-chain 96-kDa pro-form, which is activated by thrombin in the presence of negatively charged molecules to its 34-kDa active two-chain heterodimeric form (13). The HGFA activity is regulated by the HGF activator inhibitors (HAI)-1 and -2, reviewed in (12).
###end p 11
###begin p 12
###xml 5 11 5 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 13 15 13 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
Tjin et al. (14) showed that myeloma cells express HGFA and thereby proteolytically convert single chain HGF into its active form. We aimed to examine the levels of the activated form of HGFA in serum and bone marrow plasma from myeloma patients, and to correlate the serum levels with clinical stage, parameters of disease activity and survival. Secondly, we aimed to investigate a possible relationship between the concentrations of HGFA and HGF.
###end p 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 13
###begin p 14
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 471 473 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 1030 1031 1021 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
###xml 800 807 <span type="species:ncbi:9606">patient</span>
We examined serum samples drawn at diagnosis from 49 patients diagnosed with multiple myeloma in mid-Norway between 1996 and 2005. We also examined bone marrow plasma from the same patients when available (n = 16). Serum and bone marrow plasma samples were drawn before initiation of treatment and frozen at -80degreesC until they were analyzed. In six patients, we also examined serum drawn at time of first response, defined according to the EBMT/IBMTR/ABMTR criteria (15) and at first relapse, defined as the time point where treatment was re-introduced. Control samples were obtained from 24 healthy volunteers. Because of limited quantities of sample material, HGF was analyzed in only 20 of the 24 controls. Clinical information about the myeloma patients was obtained retrospectively from the patient records. Registered information was stage according to Durie Salmon and International Scoring System (ISS), type and concentrations of serum and urine M-component, plasma cell percentage in bone marrow aspirate, serum beta2-microglobulin and overall survival. The study protocol was approved by the Regional Medical Ethics Committee and the study was performed according to the declaration of Helsinki.
###end p 14
###begin p 15
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 43 46 <span type="species:ncbi:9606">men</span>
###xml 54 59 <span type="species:ncbi:9606">women</span>
###xml 113 116 <span type="species:ncbi:9606">men</span>
###xml 123 128 <span type="species:ncbi:9606">women</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 436 443 <span type="species:ncbi:9606">patient</span>
###xml 457 465 <span type="species:ncbi:9606">patients</span>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
The median age of the myeloma patients (33 men and 16 women) was 65 yr (range 30-87 yr), and of the controls (15 men and 9 women) was 68 yr (range 44-81 yr). The patients were representative of the general myeloma population with serum M-component of IgG type in 29 patients (59%), IgA in seven patients (14%), other Ig isotypes in three patients (6%), only light chain secretion in nine patients (18%) and non-secretory myeloma in one patient (2%). Twenty patients (41%) were in stage 1 according to ISS, 13 patients (26%) in stage 2 and 11 patients (22%) in stage 3; for five patients (10%), no information was available.
###end p 15
###begin p 16
We used a commercially available enzyme-linked immunosorbent assay (ELISA) for the measurement of activated HGFA (IBL, Gunma, Japan) in serum and bone marrow plasma. The assay was performed according to the manufacturer's instructions. All samples were run in duplicates. The standard curve was linear between 0.9 and 15 ng/mL, and samples were diluted to concentrations within this range. The intra-assay and interassay variation coefficients for this assay are 5.5% and 5.5% at 6.5 ng/mL according to the manufacturer. Variation coefficients for our measurements were <10%.
###end p 16
###begin p 17
HGF was measured with an ELISA from R&D systems (Minneapolis, MN, USA). The assay was performed according to the manufacturer's instructions. All samples were run in duplicates. The standard curve was linear between 0.5 and 8 ng/mL. Because of limited quantities of sample material, the measurements could not be repeated and therefore samples with HGF concentrations lower than 0.5 ng/mL and above 8 ng/mL were given the values 0.5 and 8 ng/mL. Variation coefficients for our measurements were <10%. Up to two freeze-thaw cycles of serum did not affect the measured levels of HGF or HGFA.
###end p 17
###begin p 18
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 408 409 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 417 418 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
SPSS Statistical Software version 14.0 was used for statistic calculations (SPSS Inc, Chicago, IL, USA). Comparisons between groups were performed by the Mann-Whitney U-test. Correlations between two parameters were estimated by Spearman's rank correlation analysis. Survival analysis was conducted by the Kaplan-Meier method, using median values as cut off. The level of statistical significance was set at P< 0.05. P-values were two-tailed.
###end p 18
###begin title 19
Results
###end title 19
###begin p 20
###xml 97 103 97 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1</xref>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
Serum levels of activated HGFA in patients at the time of diagnosis and in controls are shown in Fig. 1. The median HGFA concentrations in myeloma and control sera were 39.7 (range 6.2-450.0) and 17.6 ng/mL (range 4.8-280.6), respectively. The difference was statistically significant (P= 0.037). The median level of activated HGFA in bone marrow plasma of myeloma patients was 6.1 ng/mL (range 3.5-30.0) (data not shown). Thus, HGFA levels were lower in bone marrow plasma than in serum. However, serum and plasma HGFA levels cannot be directly compared, as measurement of levels in serum will be 2-3 times higher than in plasma in this assay according to the manufacturer and own validation experiments (data not shown).
###end p 20
###begin p 21
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Serum concentrations of activated HGFA measured by ELISA in 49 multiple myeloma patients and 24 age- and gender-matched controls. Bars indicate median concentration.
###end p 21
###begin p 22
###xml 156 157 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
There was no correlation between the serum levels of HGFA and disease stage according to ISS or Durie Salmon, concentration of serum M-component, serum beta2-microglobulin, percentage of plasma cells in the bone marrow or overall survival (data not shown). The HGFA levels did not covariate with disease activity in serial measurements of serum drawn at diagnosis, remission and relapse in six myeloma patients (data not shown).
###end p 22
###begin p 23
###xml 128 134 128 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2</xref>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 331 332 331 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 373 374 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 374 375 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The median HGF concentrations in myeloma and control sera were 2.5 (range 0.7-8.0) and 1.6 ng/mL (range 0.5-4.0), respectively (Fig. 2). The difference was statistically significant (P< 0.001). The median HGF concentration in bone marrow plasma was 8.0 ng/mL. There was no correlation between the levels of HGFA and HGF in serum (rs = 0.14, P= 0.26) or bone marrow plasma (rs = 0.31, P= 0.38).
###end p 23
###begin p 24
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Serum concentrations of HGF measured by ELISA in 49 myeloma patients and 20 age- and gender-matched controls. Bars indicate median concentration.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 472 478 472 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
HGF has a number of myeloma-relevant activities; however, it has to be converted to its heterodimeric form to be biologically active. Urokinase-type plasminogen activator (uPA), tissue plasminogen activator, factor XIIa and matriptase have all been shown to activate single chain HGF at low rates (11, 16-18). The most potent activator is, however, the factor XII-related serine protease HGFA, with an HGF-converting potency of more than 1000 times that of uPA (11). Tjin et al. (14) showed that myeloma cells express HGFA, thereby activating HGF. We here demonstrate for the first time that HGFA exists in its activated form in serum from myeloma patients, and that serum concentrations are higher than in healthy controls. We also found detectable activated HGFA in 16 of 16 samples of bone marrow plasma from myeloma patients.
###end p 26
###begin p 27
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
The role of HGFA in regulating HGF activity in injured tissue is well established (12). Recent data support an important function of HGFA also in solid tumours such as colorectal cancer (19) and glioblastoma (20). Among lymphomas, the HGF receptor is predominantly expressed in diffuse large B-cell lymphoma (DLBCL), and interestingly, DLBCL cells also express HGFA, possibly activating HGF produced by macrophages in the tumour microenvironment (21).
###end p 27
###begin p 28
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
The activity of HGFA is tightly regulated. Secreted as an inactive single chain pro-form, cleavage by thrombin is essential for its function. In a recent publication, the kallikrein-related peptidases 4 and 5 were shown to have HGFA-activating properties similar to thrombin (22). The activity of HGFA is also controlled by the Kunitz type serine protease inhibitors HAI-1 and HAI-2 (12).
###end p 28
###begin p 29
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
It is possible that the myeloma cells directly contribute to the elevated HGFA levels in serum of myeloma patients. However, we found no correlation between the serum HGFA concentration and disease stage or traditional markers of tumour burden. As we have measured only the activated form of HGFA, the elevated levels in myeloma patients might also mirror a higher degree of activation of pro-HGFA in patients compared with controls. The complex mechanisms regulating activation of HGF in multiple myeloma, including a potential role for the HGFA inhibitors HAI-1 and HAI-2, should be addressed in further studies.
###end p 29
###begin p 30
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
We found no correlation between serum levels of HGFA and HGF. This is partly in disagreement with Nagakawa et al. (23), who found a positive correlation between serum levels of HGF and HGFA in patients with untreated and advanced stage prostate cancer. However, the fact that we have measured total HGF, which is both single chain HGF and the active heterodimer, may obscure a positive correlation between HGFA and active HGF.
###end p 30
###begin p 31
###xml 92 100 <span type="species:ncbi:9606">patients</span>
In conclusion, activated HGFA is present at high levels in serum and bone marrow of myeloma patients. Although this study has obvious limitations because of the relatively small number of study subjects, it clearly demonstrates the presence of a necessary prerequisite for activation of the HGF system in multiple myeloma. It also points to the activation step of HGF as a possible target for therapeutic intervention.
###end p 31
###begin p 32
This work was supported by grants from the Norwegian Cancer Society, The Cancer Fund of St Olavs Hospital, The Research Council of Norway and The Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).
###end p 32
###begin title 33
References
###end title 33
###begin article-title 34
The hepatocyte growth factor/met pathway controls proliferation and apoptosis in multiple myeloma
###end article-title 34
###begin article-title 35
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor
###end article-title 35
###begin article-title 36
###xml 47 52 <span type="species:ncbi:9606">human</span>
Hepatocyte growth factor promotes migration of human myeloma cells
###end article-title 36
###begin article-title 37
Hgf inhibits bmp-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
###end article-title 37
###begin article-title 38
A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in anbl-6 cells and prevents migration and adhesion of myeloma cells
###end article-title 38
###begin article-title 39
Emerging multipotent aspects of hepatocyte growth factor
###end article-title 39
###begin article-title 40
Met, metastasis, motility and more
###end article-title 40
###begin article-title 41
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The nordic myeloma study group
###end article-title 41
###begin article-title 42
Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma
###end article-title 42
###begin article-title 43
###xml 58 63 <span type="species:ncbi:9606">human</span>
Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII
###end article-title 43
###begin article-title 44
Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIA and hepatocyte growth factor activator
###end article-title 44
###begin article-title 45
Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor
###end article-title 45
###begin article-title 46
Activation of the zymogen of hepatocyte growth factor activator by thrombin
###end article-title 46
###begin article-title 47
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator
###end article-title 47
###begin article-title 48
Guidelines on the diagnosis and management of multiple myeloma 2005
###end article-title 48
###begin article-title 49
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA
###end article-title 49
###begin article-title 50
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease
###end article-title 50
###begin article-title 51
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
###end article-title 51
###begin article-title 52
Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma
###end article-title 52
###begin article-title 53
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo
###end article-title 53
###begin article-title 54
Functional analysis of HGF/met signaling and aberrant hgf-activator expression in diffuse large b-cell lymphoma
###end article-title 54
###begin article-title 55
###xml 71 76 <span type="species:ncbi:9606">human</span>
Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases
###end article-title 55
###begin article-title 56
Serum hepatocyte growth factor activator (hgfa) in benign prostatic hyperplasia and prostate cancer
###end article-title 56

